Iodinated Dopamine D1 and D2 Receptor Imaging Agents for SPECT

  • Hank F. Kung


In vivo imaging of the dopaminergic system in the mammalian brain has been the subject of extensive studies in recent years. Not only is this part of the central nervous system (CNS) very important for normal brain function, it is also a possible primary action site for antiparkinsonian agents or neuroleptic drugs for schizophrenia. Addiction to cocaine, which is an acute social and economic problem, is related to the CNS reward system involving dopaminergic function. Binding of cocaine to the dopamine reuptake sites, which leaves more dopamine in the synaptic cleft for binding to the postsynaptic neuron, is the primary mechanism for stimulation. There is a wealth of pharmacological information about the dopamine receptor (Creese and Fraser, 1987; Beaulieu, 1987; Waddington, 1986; Waddington, 1989; Stoof and Kebabian, 1984; Waddington and O’Boyle, 1987; Waddington and O’Boyle, 1989; Sidhu et al., 1991).


Single Photon Emission Compute Tomography Dopamine Receptor Washout Rate Dopamine Receptor Binding Potential Central Nervous System 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alavi A and Kung HF (1989): Imaging of the brain with SPECT: Is it coming of age? In: Yearbook of Nuclear Medicine, Hoffer PB, ed. Chicago: Year Book Medical Publishers.Google Scholar
  2. Albert PR, Neve KA, Bunzow JR and Civelli O (1990): Coupling of a cloned rat dopamine-D2 receptor to inhibition of adenylyl cyclase and prolactin secretion. J Biol Chem 265: 2098–2104.Google Scholar
  3. Beaulieu M (1987): Clinical importance of D1 and D2 receptors. Can J Neurol Sci 14 (3 Suppl): 402–406.Google Scholar
  4. Billings J, Kung MP, Chumpradit S, Pan S and Kung HF (1989): [125I](±)FISCH: A new CNS D1 dopamine receptor imaging ligand. Life Sci 45: 711–718.Google Scholar
  5. Billings JJ, Kung M-P, Chumpradit S, Mozley D, Alavi A and Kung HF (1991): Characterization of radioiodinated TISCH: A high affinity and selective ligand for mapping CNS dopamine D1 receptor. J Neurochem 58: 227–236.CrossRefGoogle Scholar
  6. Bishop JE, Mathis CA, Gerdes JM, Whitney JM, Eaton AM and Mailman RB (1991): Synthesis and in vitro evaluation of 2,3-dimethoxy-5-(fluoroalkyl)-substituted benzamides: high affinity ligands for CNS doapmine D2 receptors. J Med Chem 34: 1612–1624.CrossRefGoogle Scholar
  7. Brucke T, Podreka I, Angelberger P, Wenger S, Topitz A, Kufferle B, Muller C and Deecke L (1991): Dopamine D2 receptor imaging with SPECT: Studies in different neuropsychiatrie disorders. J Cerb Blood Flow Met 11:220–228.CrossRefGoogle Scholar
  8. Bunzow JR, Van Tol HHM, Grandy DK, Albert P, Salon J, Christie M, Machida CA, Neve KA and Civelli O (1988): Cloning and expression of a rat D2 dopamine receptor cDNA. Nature 336: 783–787.CrossRefGoogle Scholar
  9. Chumpradit S, Kung HF, Billings J, Kung M-P and Pan S (1989a): (±)-7-Chloro-8-hydroxy-1-(4′-[125I] iodophenyl)-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine: A potential CNS D1 dopamine receptor imaging agent. J Med Chem 32: 1431–1435.Google Scholar
  10. Chumpradit S, Billings J, Kung M-P, Pan S and Kung HF (1989b): An improved CNS D1 dopamine receptor imaging ligand: [123I](±)FISCH. J Nucl Med 30: 803.Google Scholar
  11. Chumpradit S, Billings JJ, Kung M-P and Kung HF (1990): R-(+) and S-(-) TISCH: New CNS D1 dopamine receptor ligands. J Nucl Med 31: 899.Google Scholar
  12. Chumpradit S, Kung MP and Kung HF (1991): New Derivatives of SCH-23390 as CNS D1 Dopamine Receptor Ligands. J Labelled Compd Radioparm 30: 347–348.CrossRefGoogle Scholar
  13. Cordes M, Henkes H, Laudahn D, Bräu H, Kramp W, Girke W, Hierholzer J, Eichstädt H and Felix R (1991): Initial experience with SPECT examinations using [123I]IBZM as a D2-Dopamine receptor antagonist in Parkinson’s Disease. Eur J Radiol 12: 182–186.CrossRefGoogle Scholar
  14. Costa DC, Verhoeff NPLG, Cullum ID, Ell PJ, Syed GMS, Barrett J, Palazidou E, Toone B, Van Royen E and Bobeldijk M (1990): In Vivo characterization of 3-Iodo-6-methoxybenzamide 123I in humans. Eur J Nucl Med 16: 813–816.CrossRefGoogle Scholar
  15. Creese I and Fraser CM (1987): Dopamine receptors. In: Receptor Biochemistry and Methodology, Venter JC and Harrison LC, eds. New York: Alan Liss, Inc.Google Scholar
  16. Dearry A, Gingrich JA, Falardeau P, Fremeau RT Jr, Bates MD and Caron MG (1990a): Molecular cloning and expression of the gene for a human D1 Dopamine receptor. Nature 347: 72–76.CrossRefGoogle Scholar
  17. Dearry A, Edelman JL, Miller S and Burnside B (1990b): Dopamine induces light-adaptive retinomotor movements in bullfrog cones via D2 receptors and in retinal pigment epithelium via D1 receptors. J Neurochem 54: 1367–1378.CrossRefGoogle Scholar
  18. Farde L, Ehrin E, Eriksson L, Greitz T, Hall H, Hedström C-G, Litton J-E and Sedvall G (1985): Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by Positron Emission Tomography. Proc Natl Acad Sci 82: 3863–3867.CrossRefGoogle Scholar
  19. Farde L, Hall H, Ehrin E and Sedvall G (1986): Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 231: 258–261.CrossRefGoogle Scholar
  20. Farde L, Wiesel F-A, Hall H, Halldin C, Stone-Elander S and Sedvall G (1987a): No D2 receptor increase in PET study of schizophrenia. Arch Gen Psychiat 44: 671–672.CrossRefGoogle Scholar
  21. Farde L, Halldin C, Stone-Elander S and Sedvall G (1987b): PET analysis of human dopamine receptor subtypes using [11C]-SCH 23390 and [11C]-Raclopride. Psychopharmacol 92: 278–284.CrossRefGoogle Scholar
  22. Farde L and von Bahr C (1990): Distribution of remoxipride to the human brain and central D2-Dopamine receptor binding examined in vivo by PET. Acta Psychiatr Scand 358(Suppl): 67–71.CrossRefGoogle Scholar
  23. Farde L, Weisel F-A, Stone-Elander S, Halldin C, Nordström A-L, Hall H and Sedvall G (1990): D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A PET study with [11C]raclopride. Arch Gen Psychiat 47: 213–219.CrossRefGoogle Scholar
  24. Fremeau RT Jr, Duncan GE, Fomaretto MG, Dearry A, Gingrich JA, Breese GR and Caron MG (1991): Localization of D1 dopamine receptor mRNA in brain supports a role in cognitive, affective, and neuroendocrine aspects of dopaminergic neurotransmission. Proc Natl Acad Sci 88: 3772–3776.CrossRefGoogle Scholar
  25. Grandy DK, Marchionni MA, Makam H, Stofko RE, Alfano M, Frothingham L, Fischer JB, Burke-Howie KJ, Bunzow JR, Server AC and Civelli O (1989): Cloning of the cDNA and gene for a human D2 dopamine receptor. Proc Natl Acad Sci 86: 9762–9766.CrossRefGoogle Scholar
  26. Hall H and Wedel I (1986): Comparisons between the in vitro binding of two substituted benzamides and two butyrophenones to dopamine-D2 receptors in the rat striatum. Acta Pharmacol et Toxicol 58: 368–373.CrossRefGoogle Scholar
  27. Hall H, Högberg T, Halldin C, Köhler C, Ström P, Ross SB, Larsson SA and Farde L (1990): NCQ 298, a new selective iodinated salicylamide ligand for the labelling of dopamine D2 receptors. Psychopharmacol 103: 16–18.Google Scholar
  28. Joyce JN, Lexow N, Bird E and Winokur A (1988): Organization of D1 and D2 receptors in human striatum: receptor autoradiographic studies in Huntington’s disease and schizophrenia. Synapse 2: 546–557.CrossRefGoogle Scholar
  29. Kebabian JW and Calne DB (1979): Multiple receptors for dopamine. Nature 277: 93–96.CrossRefGoogle Scholar
  30. Kessler RM, Ansari MS, de Paulis T, Schmidt DE, Clanton JA, Smith HE, Manning RG, Gillespie D and Ebert MH (1991a): High affinity dopamine D2 receptor radioligands. 1. regional rat brain distribution of iodinated benzamides. J Nucl Med 32: 1593–1600.Google Scholar
  31. Kessler RM, Ansari MS, Schmidt DE, de Paulis T, Clanton JA, Innis R, Al-Tikriti M, Manning RG and Gillespie D (1991b): High affinity dopamine D2 receptor radioligands. 2. [125I]Epidepride, a potent and specific radioligand for the characterization of striatal and extrastriatal dopamine D2 receptors. Life Sci 49: 617–628.CrossRefGoogle Scholar
  32. Kung HF, Guo Y-Z, Billings J, Xu X, Mach RH, Blau M and Ackerhalt RE (1988a): Preparation and biodistribution of [125I]IBZM: a potential CNS D2 dopamine receptor imaging agent. Nucl Med Biol 15: 195–201.Google Scholar
  33. Kung HF, Billings J, Guo Y-Z, Blau M and Ackerhalt RE (1988b): Preparation and biodistribution of [125I]IBZP: a potential CNS D2 dopamine receptor imaging agent. Nucl Med Biol 15: 187–193.Google Scholar
  34. Kung HF, Alavi A, Chang W, Kung M-P, Keyes JW Jr, Velchik MG, Billings J, Pan S, Noto R, Rausch A and Reilly J (1990a): In vivo SPECT imaging of CNS D2 dopamine receptors: Initial studies with [123I]IBZM in humans. J Nucl Med 31: 573–579.Google Scholar
  35. Kung M-P, Kung HF, Billings J, Yang Y, Murphy RA and Alavi A (1990b): The characterization of IBF as a new selective dopamine D2 receptor imaging agent. J Nucl Med 31: 648–654.Google Scholar
  36. Manik CP, Molinoff PB and McGonigle P (1988): Comparison of 125I SCH 23982 and [3H]SCH 23390 as ligands for the D1 dopamine receptor. J Neurochem 51: 391–397.CrossRefGoogle Scholar
  37. Mansour A, Meador-Woodruff JH, Bunzow JR, Civelli O, Akil H and Watson SJ (1990a): Localization of dopamine D2 receptor mRNA and D1 and D2 receptor binding in the rat brain and pituitary: An in situ hybridization-receptor autoradiographic analysis. J Neurosci 10: 2587–2600.Google Scholar
  38. Mansour A, Meador-Woodruff JH, Camp DM, Robinson TE, Bunzow J, Van Tol HH, Civelli O, Akil H and Watson SJ (1990b): The effects of nigrostriatal 6-hydroxydopamine lesions on dopamine D2 receptor mRNA and opioid systems. Prog Clin Biol Res 328: 227–230.Google Scholar
  39. McQuade RD, Chipkin R, Amlaiky N, Caron M, Iorio L and Barnett A (1988a): Characterization of the radioiodinated analogue of SCH 23390: In vitro and In vivo D1 dopamine receptor binding studies. Life Sci 43: 1151–1160.CrossRefGoogle Scholar
  40. McQuade RD, Ford D, Duffy RA, Chipkin RE, Iorio LC and Barnett A (1988b): Serotonergic component of SCH 23390: In vitro and In vivo binding analyses. Life Sci 43:1861–1869.CrossRefGoogle Scholar
  41. Maziere B and Maziere M (1990): Where have we got to with neuroreceptor mapping of the human brain? Eur J Nucl Med 16: 817–835.CrossRefGoogle Scholar
  42. Monsma FJ Jr, McVittie LD, Gerfen CR, Mahan LC and Sibley DR (1989): Multiple D2 dopamine receptors produced by alternative RNA splicing. Nature 342: 926–929.CrossRefGoogle Scholar
  43. Monsma FJ Jr, Mahan LC, McVittie LD and Gerfen CR (1990a): Molecular cloning and expression of a D1 dopamine receptor linked to adenylyl cyclase activation. Proc Natl Acad Sci 87: 6723–6727.CrossRefGoogle Scholar
  44. Monsma FJ Jr, Barton AC and Sibley DR (1990b): Expression of functional D2 dopamine receptors following differentiation of y-79 human retinoblastoma cells. J Neurochem 54: 1200–1207.CrossRefGoogle Scholar
  45. Moerlein SM, Parkinson D and Welch MJ (1990): Radiosynthesis of high effective specific-activity [123I]SCH 23982 for dopamine D1 receptor-based SPECT imaging. Appl Radiat hot 41: 381–385.CrossRefGoogle Scholar
  46. Murphy RA, Kung HF, Kung M-P and Billings J (1990): Synthesis and characterization of iodobenzamide analogues: Potential D2 dopamine receptor imaging agents. J Med Chem 33: 171–178.CrossRefGoogle Scholar
  47. Nakatzuka I, Saji H, Shiba K, Shimizu H, Okuno M, Yoshitake A and Yokoyama A (1987): In vitro evaluation of radioiodinated butyrophenones as radiotracer for dopamine receptor study. Life Sci 41: 1989–1997.CrossRefGoogle Scholar
  48. Neumeyer JL, Baindur N, Yuan J, Booth G, Seeman P and Niznik HB (1990): Development of a high affinity and stereoselective photoaffinity label for the D1 dopamine receptor: Synthesis and resolution of 7-[125I]Iodo-8-hydroxy-3-methyl-1-(4′-azidophenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine. J Med Chem 33: 521–526.CrossRefGoogle Scholar
  49. Ögren SO, Hall H, Köhler C, Magnusson O, Lindbom L-O, Ängeby K and Florvall L (1984): Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain. Eur J Pharmacol 102: 459–474.CrossRefGoogle Scholar
  50. de Paulis T, Kumar Y, Johansson L, Rämsby S, Florvall L, Hall H, Ängeby-Möller K and Ögren SO (1985): Potential neuroleptic agents. 3. Chemistry and antidopaminergic properties of substituted 6-Methoxysalicylamides. J Med Chem 28: 1263–1269.CrossRefGoogle Scholar
  51. Saji H, Nakatzuka I, Shiba K, Tokui T, Horiuchi K, Yoshitake A, Torizuka K and Yokoyama A (1987): Radioiodinated 2′-iodospiperone: A new radioligand for in vivo dopamine receptor study. Life Sci 41: 1999–2006.CrossRefGoogle Scholar
  52. Sidhu A, van Oene JC, Dandridge P, Kaiser C and Kebabian JW (1986): [125I]SCH 23982: The ligand of choice for identifying the D1 dopamine receptor. Eur J Pharmacol 128: 213–220.Google Scholar
  53. Sidhu A, Sullivan M, Kohout T, Balen P and Fishman PH (1991): D1 dopamine receptors can interact with both stimulatory and inhibitory guanine nucleotide binding proteins. J Neurochem 57: 1445–1451.CrossRefGoogle Scholar
  54. Snyder SH (1990): Pharmacology. The dopamine connection. Nature 347: 121–112.CrossRefGoogle Scholar
  55. Sokoloff P, Giros B, Martres MP, Bouthenet ML and Schwartz JC (1990): Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347:146–151.CrossRefGoogle Scholar
  56. Stoof JC and Kebabian JW (1984): Two dopamine receptors: Biochemistry, physiology, and pharmacology. Life Sci 35: 2281–2296.CrossRefGoogle Scholar
  57. Swart JAA and Korf J (1989): Quantification of dopamine D2 receptors by irreversible tracer binding in the living human brain: The model-dependent correction of metabolites. J Cereb Blood Flow Metab 9: 906–908.CrossRefGoogle Scholar
  58. Sunahara RK, Niznik HB, Weiner DM, Stormann TM, Brann MR, Kennedy JL, Gelernter JE, Rozmahel R, Yang YL, Israel Y, Seeman P and O’Dowd BF (1990a): Human dopamine D1 receptor encoded by an intronless gene on chromosome 5. Nature 347: 80–83.CrossRefGoogle Scholar
  59. Sunahara RK, Murphy BJ and Tuana BS (1990b): A sensitive and rapid method for identification and characterization of low abundance receptors. Anal Biochem 185: 143–146.CrossRefGoogle Scholar
  60. Sunahara RK, Guan HC, O’Dowd BF, Seeman P, Laurier LG, Ng G, George SR, Torchia J, Van Tol HH and Niznik HB (1991): Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature 350: 614–619.CrossRefGoogle Scholar
  61. Thonoor CM, Couch MW, Greer DM, Thomas KD and Williams CM (1988): biodistribution and radiation dosimetry of radioiodinated-SCH 23982, a potential dopamine D1 receptor imaging agent. J Nucl Med 29: 1668–1674.Google Scholar
  62. Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB and Civelli O (1991b): cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350: 610–614.Google Scholar
  63. Verhoeff NPLG, Bobeldijk M, Feenstra MGP, Boer GJ, Maas MAW, Erdtsieck-Ernste E, de Bruin K, and van Royen EA (1991): In vitro and in vivo D2-dopamine receptor binding with [123I]S(-)iodobenzamide) [123I]IBZM) in rats and human brain. Nucl Med Biol 18: 837–846.Google Scholar
  64. Verhoeff NPLG (1991): Pharmacological implication for neuroreceptor imaging. Eur J Nucl Med 18: 482–502.CrossRefGoogle Scholar
  65. Wagner HN Jr, Burns HD, Dannals RF, Wong DF, Langstrom B, Duelfer T, Frost JJ, Ravert HT, Links JM, Rosenbloom SB, Lukas SE, Kramer AV and Kuhar MJ (1983): Imaging dopamine receptors in the human brain by positron tomography. Science 221: 1264–1266.CrossRefGoogle Scholar
  66. Waddington JL (1986): Behavioural correlates of the action of selective D1 dopamine receptor antagonists: Impact of SCH 23390 and SKF 83566, and functionally interactive D1:D2 receptor systems. Biochem Pharmacol 35: 3661–3667.CrossRefGoogle Scholar
  67. Waddington JL and O’Boyle KM (1987): The D1 dopamine receptor and the search for its functional role: From neurochemistry to behaviour. Rev Neurosci 1: 157–184.CrossRefGoogle Scholar
  68. Waddington JL (1989): Sight and insight: brain dopamine receptor occupancy by neuroleptics visualised in living schizophrenic patients by Positron Emission Tomography. Br J Psychiat 154:433–436.CrossRefGoogle Scholar
  69. Waddington JL and O’Boyle KM (1989): Drugs acting on brain dopamine receptors: a conceptual re-evaluation five years after the first selective D1 antagonist. Pharmac Ther 43: 1–52.CrossRefGoogle Scholar
  70. Weiner DM, Levey AI, Sunahara RK, Niznik HB, O’Dowd BF, Seeman P and Brann MR (1991): D1 and D2 dopamine receptor mRNA in rat brain. Proc Natl Acad Sci 88: 1859–1863.CrossRefGoogle Scholar
  71. Wong DF, Wagner HN Jr, Pearlson G, Dannals RF, Links JM, Ravert HT, Wilson AA, Suneja S, Bjorvvinsen E, Kuhar MJ and Tune L (1985): Dopamine receptor binding of C-11–3-N-methylspiperone in the caudate in schizophrenia and bipolar disorder: A preliminary report. Psychopharmacol Bull 21: 595–598.Google Scholar
  72. Wong DF, Wagner HN Jr, Tune LE, Dannals RF, Pearlson GD, Links JM, Tamminga CA, Broussole EP, Ravert HT, Wilson AA, Toung JKT, Malat J, Williams JA, O’Tuama LA, Snyder SH, Kuhar MJ and Gjedde A (1986): Positron Emission Tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 234: 1558–1563.CrossRefGoogle Scholar
  73. Wong DF, Minkin E, Wilson AA, Young LT, Dannals RF, Ravert HT and Wagner HN Jr (1990): In vivo studies of D2 dopamine receptors with C-11 and I-125 Iodobenzamide. J Nucl Med 31: 882.Google Scholar
  74. Young LT, Wong DF, Goldman S, Minkin E, Chen C, Matsumura K, Scheffel U and Wagner HN Jr (1991): Effects of endogenous dopamine on kinetics of 3H N-methylspiperone and 3Hraclopride binding in the rat brain. Synapse 9: 188–94.CrossRefGoogle Scholar
  75. Zhou GZ, Katki AG, Schwarz S, Munson PJ and Rodbard D (1991): Quantitative characterization of multiple binding sites for phencyclidine and n-allylnormetazocine in membranes from rat and guinea pig brain. Neuropharmacol 30: 775–786.CrossRefGoogle Scholar

Copyright information

© Birkhäuser Boston 1993

Authors and Affiliations

  • Hank F. Kung
    • 1
  1. 1.Departments of Radiology and PharmacologyUniversity of PennsylvaniaUSA

Personalised recommendations